24/7 Market News Snapshot 01 April, 2025 – GRI Bio, Inc. Common Stock (NASDAQ:GRI)

April 1, 2025

DENVER, Colo., 01 April, 2025 (247marketnews.com) – (NASDAQ:GRI) are discussed in this article.
In a notable market upswing, GRI Bio, Inc. has witnessed a dramatic increase in its stock price, surging from an opening value of $3.235 to an impressive high of $9.298, reflecting a remarkable gain of 190.56%. This follows a close of $3.200, and amidst a trading volume of 2.73 million shares, the substantial jump indicates a strong wave of investor interest and enthusiasm surrounding the company’s future prospects.

This surge coincides with the company’s recent positive developments in clinical research. GRI Bio is advancing its Phase 2a clinical study of GRI-0621, a promising small molecule treatment for Idiopathic Pulmonary Fibrosis (IPF). The Independent Data Monitoring Committee (IDMC) has reviewed the interim results, endorsing the continuation of the trial without safety concerns. Targeted at modulating the activity of Type 1 Invariant NKT (iNKT) cells, GRI-0621 seeks to address the unmet medical needs faced by patients with IPF.

Interim findings reveal that GRI-0621 has been safe and well-tolerated among the initial twelve patients assessed. Importantly, key biomarker evaluations related to lipid levels demonstrated no significant changes, further substantiating the drug’s safety profile. Marc Hertz, PhD, CEO of GRI Bio, expressed optimism regarding GRI-0621’s potential impact, calling it a possible breakthrough for patients dealing with limited treatment options and significant unmet needs.

The study intends to enroll approximately 36 subjects, randomized into treatment and placebo groups, with treatment spanning 12 weeks. As GRI Bio continues to make strides in its clinical programs, the company looks forward to sharing additional biomarker data in the second quarter of 2025 and anticipates topline results in the third quarter. GRI Bio remains committed to redefining therapeutic approaches in the battle against IPF and other serious diseases.

Related news for (GRI)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.